Cyclerion Looking To Partner Praliciguat Despite Phase II Fail In Diabetic Nephropathy
Executive Summary
The Ironwood spinout thinks its sGC stimulator demonstrated benefit in reducing urine albumin levels in DN patients; notes data improve markedly if one outlier trial site is excluded.